Keyword: Giovanni Caforio

15. Bristol-Myers Squibb

You could almost say that Bristol-Myers Squibb’s story is all about immuno-oncology, what with the high-profile cancer-fighter Opdivo grabbing most of its 2017 headlines. But a come-from-behind anticoagulant, Eliquis, is pulling almost-equal weight these days, and together they pushed the company to a 7% revenue rise in 2017. 

14. Giovanni Caforio

Last year, Opdivo racked up billions in sales and a range of new indications, and that helped boost Bristol-Myers Squibb CEO Giovanni Caforio's salary base by 17%.